Provided by Tiger Trade Technology Pte. Ltd.

BioVie Inc

1.91
-0.0600-3.05%
Pre-market: 1.960.0460+2.41%04:54 EDT
Volume:261.85K
Turnover:506.01K
Market Cap:16.14M
PE:-0.63
High:1.99
Open:1.95
Low:1.89
Close:1.97
52wk High:3.79
52wk Low:0.8200
Shares:8.45M
Float Shares:8.41M
Volume Ratio:0.75
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0500
EPS(LYR):-3.0500
ROE:-150.76%
ROA:-79.06%
PB:1.57
PE(LYR):-0.63

Loading ...

Biovica Q1 FY27 Operating Loss Widens to SEK 20.33 Million; Net Sales Rise 56% to SEK 4.04 Million

Reuters
·
Yesterday

BioVie Seeks FDA End-of-Phase 2 Meeting to Advance Bezisterim Phase 3 Parkinson’s Trial Design

Reuters
·
Sep 08

BioVie Announces Update to Parkinson’s Phase 3 Development Program

THOMSON REUTERS
·
Sep 08

BioVie - Requests End-of-Phase 2 Meeting with FDA, Expects Feedback Before Year-End

THOMSON REUTERS
·
Sep 08

BioVie Completes Treatment Phase of Phase 2 Long COVID Trial for Bezisterim

Reuters
·
Aug 31

BioVie - Topline Results for Address-Lc Expected Before End of September 2026

THOMSON REUTERS
·
Aug 31

BioVie Announces Completion of Treatment Phase of Address-Lc Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long Covid

THOMSON REUTERS
·
Aug 31

BioVie President and CEO Cuong V Do Acquires 15,210 Shares Worth $31,637.68

Reuters
·
Aug 29

Top Premarket Gainers

MT Newswires Live
·
Aug 19

BioVie Q4 EPS $(0.70) Up From $(1.42) YoY

Benzinga Earnings
·
Aug 13

BioVie FY26 Net Loss Widens to $22.1 Million; Operating Expenses Rise to $22.7 Million

Reuters
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

NASDAQ Trade Halt Volatility Trading Pause at 09:47 Am

Reuters
·
Aug 12

BioVie Posts Corporate Presentation Outlining Bezisterim and Biv201 Clinical Programs

Reuters
·
Aug 06

BioVie Says Phase 2 Sunrise-PD Trial Shows Bezisterim Improves Motor and Non-Motor Symptoms in Early Parkinson’s Disease

Reuters
·
Aug 06

BioVie - Bezisterim Well Tolerated with Safety Profile Comparable to Placebo

THOMSON REUTERS
·
Aug 06

BioVie - Bezisterim Shows Statistically Significant Improvements in Motor and Non-Motor Symptoms vs Placebo

THOMSON REUTERS
·
Aug 06

BioVie Announces Topline Results of Phase 2 Sunrise-Pd Trial of Bezisterim in Early Parkinson’s Disease

THOMSON REUTERS
·
Aug 06

BioVie - Bezisterim Reduces Biomarkers of Neurodegeneration and Inflammation

THOMSON REUTERS
·
Aug 06

BioVie - Phase 2 Trial Meets Prespecified Endpoints with Bezisterim Improving Inflammatory and Biological Markers

THOMSON REUTERS
·
Aug 06